MolecularRift, a Gesture Based Interaction Tool for Controlling Molecules in 3-D

Visualization of molecular models is a vital part in modern drug design. Improved visualization methods increases the conceptual understanding and enables faster and better decision making. The introduction of virtual reality goggles such as Oculus Rift has introduced new opportunities for the capabilities of such visualisations. A new interactive visualization tool (MolecularRift), which lets the user experience molecular models in a virtual reality environment, was developed in collaboration with AstraZeneca. In an attempt to create a more natural way to interact with the tool, users can steer and control molecules through hand gestures. The gestures are recorded using depth data from a Mircosoft Kinect v2 sensor and interpreted using per pixel algorithms, which only focus on the captured frames thus freeing the user from additional devices such as cursor, keyboard, touchpad or even piezoresistive gloves. MolecularRift was developed from a usability perspective using an iterative developing process and test group evaluations. The iterations allowed an agile process where features easily could be evaluated to monitor behavior and performance, resulting in a user-optimized tool. We conclude with reflections on virtual reality's capabilities in chemistry and possibilities for future projects.Virtual reality är framtiden. Nya tekniker utvecklas konstant och parallellt med att datakapaciteten förbättras finner vi nya sätt att använda dem ihop. Vi har utvecklat ett nytt interaktivt visualiserings verktyg (Molecular Rift) som låter användaren uppleva molekylära modeller i en virtuell verklighet. I dagens medicinindustri är man i ständigt behov av nya metoder för att visualisera potentiella läkemedel i 3-D. Det finns flera verktyg idag som används för att visualisera molekyler i 3-D stereo. Våra nyframtagna tekniker inom virtuell verklighet presenterar möjligheter för medicinutvecklare att ”gå in” i de molekylära strukturerna och uppleva dem på ett helt nytt sätt

Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine

In 1951, Max Theiler of the Rockefeller Foundation received the Nobel Prize in Physiology or Medicine for his discovery of an effective vaccine against yellow fever—a discovery first reported in the JEM 70 years ago. This was the first, and so far the only, Nobel Prize given for the development of a virus vaccine. Recently released Nobel archives now reveal how the advances in the yellow fever vaccine field were evaluated more than 50 years ago, and how this led to a prize for Max Theiler

Rat Mesentery Angiogenesis Assay

The adult rat mesentery window angiogenesis assay is biologically appropriate and is exceptionally well suited to the study of sprouting angiogenesis in vivo [see review papers], which is the dominating form of angiogenesis in human tumors and non-tumor tissues, as discussed in invited review papers1,2. Angiogenesis induced in the membranous mesenteric parts by intraperitoneal (i.p.) injection of a pro-angiogenic factor can be modulated by subcutaneous (s.c.), intravenous (i.v.) or oral (p.o.) treatment with modifying agents of choice. Each membranous part of the mesentery is translucent and framed by fatty tissue, giving it a window-like appearance

Customized eye models for determining optimized intraocular lenses power

We have developed a new optical procedure to determine the optimum power of intraocular lenses (IOLs) for cataract surgery. The procedure is based on personalized eye models, where biometric data of anterior corneal shape and eye axial length are used. A polychromatic exact ray-tracing through the surfaces defining the eye model is performed for each possible IOL power and the area under the radial MTF is used as a metric. The IOL power chosen by the procedure maximizes this parameter. The IOL power for 19 normal eyes has been determined and compared with standard regression-based predictions. The impact of the anterior corneal monochromatic aberrations and the eye’s chromatic aberration on the power predictions has been studied, being significant for those eyes with severe monochromatic aberrations, such as post-LASIK cataract patients, and for specific IOLs with low Abbe numbers

Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo

Norrby K, Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010; 118: 949–57

Invasive Group B Streptococcal Disease in Non-pregnant Adults: A Review with Emphasis on Skin and Soft-tissue Infections

Streptococcus agalactiae, commonly referred as group B Streptococcus (GBS), is a major cause of neonatal sepsis and infections in pregnant women. However, the number of invasive infections in non-pregnant adults is growing. Elderly patients and those with chronic underlying conditions, such as diabetes mellitus or compromised immune defence, are at increased risk of invasion. The spectrum of clinical manifestations is broad and includes necrotizing fasciitis and toxic shock syndrome. Although, primary bacteremia and skin and soft-tissue infections are the most frequently reported diagnosis. This article reviews the epidemiology, pathogenesis and treatment of invasive GBS disease in non-pregnant adults, with an emphasis on skin and soft-tissue infection

Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin

The clinical and bacteriological efficacy and safety of the antibiotics ceftazidime or imipenem/cilastatin in seriously ill patients with nosocomial infections were compared in a prospective, open, evaluator-blind, multicentre comparative trial. The study was performed in 26 European centres, the majority being intensive care units. Subjects were randomized to receive either ceftazidime 2 g bid or imipenem cilastatin 0·5 g qid given for at least five days after stratification for pneumonia, septicaemia or urinary tract infection (UTI). Three hundred and ninety-three patients with serious nosocomial infections (254 with pneumonia; 91 with septicaemia and 48 UTI were treated between February 1988 and January 1990 and their clinical and bacteriological response to antibiotic treatment assessed. There were no significant differences between ceftazidime and imipenem/cilastatin in clinical efficacy. The failure rates in evaluable patients were 22 and 26% in pneumonia, 23 and 19% in septicaemia and 0 and 5% respectively in those with UTI. Overall there was no significant difference between the two antibiotics for bacteriological response in the three infection strata. However, in patients with pneumonia ceftazidime was significantly more effective than imipenem/cilastatin in clearing patients of Pseudomonas spp.: 3/17 and 11/19 patients respectively had persistent growth of Pseudomonas spp. post-treatment (P = 0·004), and in one ceftazidime failure resistance emerged compared to six imipenem/cilastatin failures in which resistance emerged. Few drug-related adverse events were recorded in either treatment group. Monotherapy with either ceftazidime (2 g bid) or imipenem/cilastatin (0·5 g qid) is safe and effective and could be considered as an alternative to combination therapy for the treatment of serious hospital-acquired infection

the chromosomes of the cynomolgus macaque macaca fascicularis

The Cynomolgus or crab-eating macaque, Macaca fascicularis (M. irus) has 42 chromosomes. The X chromosome is submetacentric and about 5 % in length of the complement. One of the X chromosomes is very late replicating in the female somatic cells. The other X is also relatively late replicating. The Y chromosome is a minute acrocentric. A short metacentric chromosome was also found to be late replicating. Chromosome no. 20 has an obvious secondary constriction which often associates in a characteristic way. The sex bivalent is identified at pachytene as a characteristic "sex vesicle". At diakinesis it shows an end-to-end association. The mean number of chiasmata per cell was 40 at diakinesis-first metaphase

Extracellular adherence protein (Eap) from Staphylococcus aureus does not function as a superantigen

AbstractExtracellular adherence protein (Eap) from Staphylococcus aureus has been reported to have strong anti-inflammatory properties, which make Eap a potential anti-inflammatory agent. However, Eap has also been demonstrated to trigger T-cell activation and to share structural homology with superantigens. In this study, we focused on whether Eap fulfilled the definition criteria for a superantigen. We demonstrate that T-cell activation by Eap is dependent on both major histocompatibility complex class II and intercellular adhesion molecule type 1, that cellular processing is required for Eap to elicit T-cell proliferation, and that the kinetics of proliferation resemble the profile of a conventional antigen and not that of a superantigen